MedTrace Logo

A Study to Evaluate the Efficacy and Safety of UI022/UI023

NCT07600385 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 260

Last updated 2026-05-20

No results posted yet for this study

Summary

Efficacy and Safety of Combined Cilostazol and Rosuvastatin Therapy Versus Rosuvastatin Alone in Patients with Chronic Lower Extremity Peripheral Artery Disease: A Multicenter, Double-Blind, Randomized Controlled Trial

Conditions

  • Peripheral Arterial Disease

Interventions

DRUG

UI022 or UI023 and co-administration of matching placebo

Run-in period: UIC201802 1 Tab/day + UIC201604 1 Tab/day, or UIC201803 1 Tab/day + UIC201801 1 Tab/day, for 4 weeks Treatment period: UI022 1 Tab/day + UIC201804 1 Tab/day, or UI023 1 Tab/day + UIC201805 1 Tab/day, for 24 weeks

DRUG

UIC201604 or UIC201801 and co-administration of matching placebo

Run-in period: UIC201802 1 Tab/day + UIC201604 1 Tab/day, or UIC201803 1 Tab/day + UIC201801 1 Tab/day, for 4 weeks Treatment period: UIC201604 1 Tab/day + UIC201802 1 Tab/day, or UIC201801 1 Tab/day + UIC201803 1 Tab/day, for 24 weeks

Sponsors & Collaborators

  • Korea United Pharm. Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-12
Primary Completion
2022-05-03
Completion
2022-05-03

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07600385 on ClinicalTrials.gov